title: Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy.
abstract: Messenger RNA (mRNA)-transfected dendritic cell (DC) vaccines have been shown to be a powerful modality for eliciting antitumor immune responses in mice and humans; however, their application has not been fully optimized since many of the factors that contribute to their efficacy remain poorly understood. Work stemming from our laboratory has recently demonstrated that preconditioning the vaccine site with a recall antigen prior to the administration of a dendritic cell vaccine creates systemic recall responses and resultantly enhances dendritic cell migration to the lymph nodes with improved antitumor efficacy. This chapter describes the generation of murine mRNA-transfected DC vaccines, as well as a method for vaccine site preconditioning with protein antigen formulations that create potent recall responses.
authors.affiliation: Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC, 27710, USA.|Department of Pathology, Duke University Medical Center, Durham, NC, USA.
authors.forename: Kristen A
authors.initials: KA
authors.lastname: Batich
authors.affiliation: Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC, 27710, USA.|Department of Pathology, Duke University Medical Center, Durham, NC, USA.
authors.forename: Adam M
authors.initials: AM
authors.lastname: Swartz
authors.affiliation: Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC, 27710, USA. john.sampson@duke.edu.|Department of Pathology, Duke University Medical Center, Durham, NC, USA. john.sampson@duke.edu.|Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA. john.sampson@duke.edu.|Department of Immunology, Duke University Medical Center, Durham, NC, USA. john.sampson@duke.edu.|The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. john.sampson@duke.edu.
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D019496:Cancer Vaccines / Q000276:immunology*; D002454:Cell Differentiation; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D004586:Electrophoresis; D005434:Flow Cytometry; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009369:Neoplasms / Q000276:immunology*; D010641:Phenotype; D012333:RNA, Messenger / Q000235:genetics; D014158:Transcription, Genetic; D014162:Transfection / Q000379:methods*; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines; D012333:RNA, Messenger
keywords: Bone marrow; Dendritic cells; Electroporation; Intradermal; Preconditioning; Protein antigen formulation; Transcription; mRNA